A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

Eric Lawitz, Fred Poordad, Phillip S. Pang et al. · The Lancet · 2013 · 549 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

Kazuaki Chayama, Shoichi Takahashi, Joji Toyota et al. · Hepatology · 2011 · 335 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Serial Studies of Hepatitis-Associated Antigen and Antibody in Patients Receiving Antitumor Chemotherapy for Myeloproliferative and Lymphoproliferative Disorders

Jack R. Wands, Catherine M. Chura, F J Roll et al. · Gastroenterology · 1975 · 256 citations

Medicine, Immunology, Oncology +10

FULMINANT HEPATIC FAILURE IN LEUKAEMIA AND CHORIOCARCINOMA RELATED TO WITHDRAWAL OF CYTOTOXIC DRUG THERAPY

R M Galbraith, Roger Williams, A.L.W.F. Eddleston et al. · The Lancet · 1975 · 250 citations

Pharmacy, Oncology, Pharmacology +7

Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir: Figure 1.

Jeffrey M. Collins, Kara Loren Raphael, Charles Sanford Terry et al. · Clinical Infectious Diseases · 2015 · 167 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17